

# Impact of secondhand smoke on cystic fibrosis: is there a link to fatty acid metabolism?

Stefan Zielen,<sup>1</sup> Daniela Fussbroich<sup>1,2</sup>

Cystic fibrosis (CF) is an autosomal recessive disease caused by genetic mutations of the *cystic fibrosis transmembrane conductance regulator* (CFTR) gene leading to viscous secretions, chronic respiratory infections and airway inflammation. Although survival of patients has been markedly improved due to better care and new treatment options, lung failure is still the major cause of mortality.

Thus, controlling respiratory infection and excessive airway inflammation is an important goal in the treatment of CF lung disease. Interestingly, heterogeneity in disease severity has been noted for a long time and airway inflammation may already be present in young children even in the absence of infection.<sup>1</sup> Multiple factors have been proposed to explain the variety of disease severity even in young patients. These factors include differences in CFTR mutations, poor compliance with treatment, external factors like early viral infections and environmental factors like secondhand smoke exposure (SHSe). Many clinicians believe that SHSe is a major contributing factor for disease progression, although the mechanisms associated with increased inflammation and infection due to SHSe in infants and young children with CF is not fully elucidated. Kopp *et al*<sup>2</sup> in this issue are the first who were able to close this important gap. They could clearly demonstrate that SHSe is highly prevalent in young children with CF and results in alterations of arachidonic acid (AA) metabolism and inflammatory gene expression, which in turn impairs bacterial clearance.

Since the famous study of Freedman *et al*,<sup>3</sup> which was published in 2004, it is well known that patients with CF suffer from a disturbed lipid metabolism. This includes an altered lipid constitution with low amounts of linoleic and

docosahexaenoic acid and an altered cholesterol and sphingolipid metabolism. However, Kopp *et al*<sup>2</sup> were able to show that SHSe aggravates these findings and demonstrate why SHSe is especially detrimental to children with CF. In order to examine whether SHSe alters the endogenous biosynthesis of lipid mediators derived from AA, they determined lipid mediator profiles of patients' serum and found that SHSe decreased AA-derived prostaglandin (PG) D<sub>2</sub> and leukotriene (LT) C<sub>4</sub> lipid mediators as well as their monohydroxy precursors in patients with CF. Of note, the authors analysed secondhand smoke by longer-term exposure measures in the hair of patients and controls, which is much more representative than measures in saliva or urine.

Kopp *et al*<sup>2</sup> particularly found decreased PGD<sub>2</sub> serum levels which could be associated with impaired clinical outcome, such as hospitalisation for pulmonary exacerbation in infants with CF and children exposed to SHS. Furthermore, they demonstrated a dose-dependent decrease of PGD<sub>2</sub> with increasing concentrations of cigarette smoke extract (CSE) in *in vitro* experiments with CSE-exposed macrophages. This finding is surprising since the physiological role of PGD<sub>2</sub> remains controversial. Many studies have reported that PGD<sub>2</sub> is a key player of the TH-2-driven inflammatory response in asthma, mediating bronchoconstriction and eosinophilia. Therefore, PGD<sub>2</sub> is a promising new therapeutic target in asthma.<sup>4</sup> In contrast, other groups have reported that PGD<sub>2</sub> facilitates resolution of inflammation through the PRKAR2A-mediated suppression of JAK2/STAT1 signalling by inhibiting the recruitment of dendritic cells and neutrophils.<sup>5</sup> At present, the pro-inflammatory and/or anti-inflammatory effects of PGD<sub>2</sub> are difficult to understand. Although the paper of Kopp *et al*<sup>2</sup> does not provide a definite answer, it is important to note that not only PGD<sub>2</sub> was downregulated. The manuscript's findings are especially interesting since CFTR itself seems to be involved in the regulation of the PGD<sub>2</sub> synthase-PGD<sub>2</sub>-15d-PGJ<sub>2</sub> pathway.<sup>6</sup>

Further lipidomics analysis revealed a decrease of lipoxin (LX) A<sub>4</sub>, LTE<sub>4</sub> and PGE<sub>2</sub> in CF compared with non-CF macrophages *in vitro*. Thereby, the authors demonstrated that the COX-2-dependent and also the 5-lipoxygenase-dependent endogenous biosynthesis of lipid mediators derived from AA is impacted by cigarette smoke in a decreasing manner. Especially regarding pro-resolving actions, specialised pro-resolving mediators, such as LXA<sub>4</sub>, are described to orchestrate resolution processes, such as clearance of microbes and cellular debris by macrophages.<sup>7–10</sup> Moreover, the administration of 1 nM LXA<sub>4</sub> has been shown to have protective effects against *Pseudomonas aeruginosa* bacterial challenge together with a delaying action against bacterial invasion in CF airway epithelial cells from patients with CF.<sup>7</sup>

Taken together, Kopp *et al*<sup>2</sup> showed for the first time that infants and children with CF and SHS exposure biosynthesize significantly lower amounts of AA-derived lipid mediators, have dysregulated inflammatory gene expression and have impaired bacterial clearance. By correlation of PGD<sub>2</sub> levels with clinical outcome, the authors could show the high impact of altered AA-dependent lipid mediator pathways in infants and children with CF, particularly by SHSe.

Since the biosynthesis of pro-inflammatory as well as pro-resolving lipid mediator pathways were negatively affected by SHSe, further clarification would be valuable to identify specific functions of distinct AA-derived lipid mediators in smoke-exposed patients with CF.

**Contributors** SZ and DF wrote the manuscript and contributed equally to the critical revision and the final approval.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Zielen S, Fussbroich D. *Thorax* 2019;74:529–530.

Accepted 1 April 2019  
Published Online First 30 April 2019



► <http://dx.doi.org/10.1136/thoraxjnl-2018-211845>

<sup>1</sup>University Hospital Frankfurt, Division of Paediatric Pulmonology, Allergy, and Cystic Fibrosis, Goethe University Frankfurt, Frankfurt am Main, Germany  
<sup>2</sup>Department of Food Technology, Fulda University of Applied Sciences, Fulda, Germany

**Correspondence** to Dr Stefan Zielen, University Hospital, Division of Paediatric Pulmonology, Allergy, and Cystic Fibrosis, Goethe University Frankfurt, Frankfurt 60323, Germany; stefan.zielen@kfgu.de

*Thorax* 2019;**74**:529–530.  
doi:10.1136/thoraxjnl-2019-213042

## REFERENCES

- 1 Khan TZ, Wagener JS, Bost T, *et al.* Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 1995;151:1075–82.
- 2 Kopp BT, Thompson R, Kim J, *et al.* Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis. *Thorax* 2019;74:237–46.
- 3 Freedman SD, Blanco PG, Zaman MM, *et al.* Association of cystic fibrosis with abnormalities in fatty acid metabolism. *N Engl J Med* 2004;350:560–9.
- 4 Domingo C, Palomares O, Sandham DA, *et al.* The prostaglandin D<sub>2</sub> receptor  $\gamma$  pathway in asthma: a key player in airway inflammation. *Respir Res* 2018;19.
- 5 Kong D, Shen Y, Liu G, *et al.* PKA regulatory II $\alpha$  subunit is essential for PGD<sub>2</sub>-mediated resolution of inflammation. *J Exp Med* 2016;213:2209–26.
- 6 Baudouin-Legros M, Colas J, Moriceau S, *et al.* Long-term CFTR inhibition modulates 15d-prostaglandin J2 in human pulmonary cells. *Int J Biochem Cell Biol* 2012;44:1009–18.
- 7 Higgins G, Fustero Torre C, Tyrrell J, *et al.* Lipoxin A4 prevents tight junction disruption and delays the colonization of cystic fibrosis bronchial epithelial cells by *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol* 2016;310:L1053–61.
- 8 Eickmeier O, Fussbroich D, Mueller K, *et al.* Pro-resolving lipid mediator resolvin D1 serves as a marker of lung disease in cystic fibrosis. *PLoS One* 2017;12:e0171249.
- 9 Serhan CN, Chiang N, Dalli J, *et al.* Lipid mediators in the resolution of inflammation. *Cold Spring Harb Perspect Biol* 2014;7.
- 10 Philippe R, Urbach V. Specialized pro-resolving lipid mediators in cystic fibrosis. *Int J Mol Sci* 2018;19. doi:10.3390/ijms19102865. [Epub ahead of print: 21 Sep 2018].